CAR engineered T cell therapy has developed rapidly in recent years. Use of chimeric antigen receptors (CARs) as the basis of targeted adoptive T cell therapies has enabled dramatic efficacy against multiple hematopoietic malignancies, but potency against solid tumors has lagged, potentially due to insufficient CAR-T cell expansion and persistence. To improve CAR-T cell efficacy, Creative Biolabs is proud to present a new generation CAR-T cells to express interleukin (IL)-7 and CCL19 (7 × 19 CAR-T cells), as these factors are essential for the maintenance of T-cell zones in lymphoid organs, with superior anti-tumor activity compared to conventional CAR-T cells.
Studies have shown that IL-7 and CCL19 are produced by T-region fibroblast reticulocytes, which are essential for the formation and maintenance of T-cell regions in lymphoid organs, in which T cells and DCs can be recruited from the periphery. Therefore, to improve CAR-T cell efficacy, we develop potent functional elements based on IL-7 and CCL19 signaling domains, which can mimic the function of T-zone reticular cells, and recruit T cells and DCs to tumor tissues to improve the therapeutic effect of CAR-T cells against solid tumors.
To obtain 7 × 19 CAR constructs, we generate a tandem construct encoding the CAR, IL-7, and CCL19 with two 2A peptide sequence between the genes. This novel, regulatable 7 × 19 system may promote the infiltration of dendritic cells (DC) and T cells into tumor tissues.
Fig.1 Schematic Schemas of conventional (Conv.) and 7×19 CAR (7×19) gene constructs. (Adachi, 2018)
Creative Biolabs is a leading company which is dedicated to helping our worldwide customers shorten the discovery and development time in CAR-T cell therapy. We utilize unrivaled, proprietary drug design, study data, product candidate, advanced project life-cycle management, as well as real-time data to ensure the ideal outcomes. Through our full spectrum of early discovery, nonclinical and commercialization services, we are committed to developing the most promising CAR-T cell therapy product candidate for our clients.
For more detailed information, please feel free to contact us or directly send us an inquiry.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE